311 related articles for article (PubMed ID: 35420638)
1. Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants.
Momozawa Y; Sasai R; Usui Y; Shiraishi K; Iwasaki Y; Taniyama Y; Parsons MT; Mizukami K; Sekine Y; Hirata M; Kamatani Y; Endo M; Inai C; Takata S; Ito H; Kohno T; Matsuda K; Nakamura S; Sugano K; Yoshida T; Nakagawa H; Matsuo K; Murakami Y; Spurdle AB; Kubo M
JAMA Oncol; 2022 Jun; 8(6):871-878. PubMed ID: 35420638
[TBL] [Abstract][Full Text] [Related]
2. Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic
Alenezi WM; Fierheller CT; Revil T; Serruya C; Mes-Masson AM; Foulkes WD; Provencher D; El Haffaf Z; Ragoussis J; Tonin PN
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456503
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Silvestri V; Leslie G; Barnes DR; ; Agnarsson BA; Aittomäki K; Alducci E; Andrulis IL; Barkardottir RB; Barroso A; Barrowdale D; Benitez J; Bonanni B; Borg A; Buys SS; Caldés T; Caligo MA; Capalbo C; Campbell I; Chung WK; Claes KBM; Colonna SV; Cortesi L; Couch FJ; de la Hoya M; Diez O; Ding YC; Domchek S; Easton DF; Ejlertsen B; Engel C; Evans DG; Feliubadalò L; Foretova L; Fostira F; Géczi L; Gerdes AM; Glendon G; Godwin AK; Goldgar DE; Hahnen E; Hogervorst FBL; Hopper JL; Hulick PJ; Isaacs C; Izquierdo A; James PA; Janavicius R; Jensen UB; John EM; Joseph V; Konstantopoulou I; Kurian AW; Kwong A; Landucci E; Lesueur F; Loud JT; Machackova E; Mai PL; Majidzadeh-A K; Manoukian S; Montagna M; Moserle L; Mulligan AM; Nathanson KL; Nevanlinna H; Ngeow J; Nikitina-Zake L; Offit K; Olah E; Olopade OI; Osorio A; Papi L; Park SK; Pedersen IS; Perez-Segura P; Petersen AH; Pinto P; Porfirio B; Pujana MA; Radice P; Rantala J; Rashid MU; Rosenzweig B; Rossing M; Santamariña M; Schmutzler RK; Senter L; Simard J; Singer CF; Solano AR; Southey MC; Steele L; Steinsnyder Z; Stoppa-Lyonnet D; Tan YY; Teixeira MR; Teo SH; Terry MB; Thomassen M; Toland AE; Torres-Esquius S; Tung N; van Asperen CJ; Vega A; Viel A; Vierstraete J; Wappenschmidt B; Weitzel JN; Wieme G; Yoon SY; Zorn KK; McGuffog L; Parsons MT; Hamann U; Greene MH; Kirk JA; Neuhausen SL; Rebbeck TR; Tischkowitz M; Chenevix-Trench G; Antoniou AC; Friedman E; Ottini L
JAMA Oncol; 2020 Aug; 6(8):1218-1230. PubMed ID: 32614418
[TBL] [Abstract][Full Text] [Related]
4. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
5. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
[TBL] [Abstract][Full Text] [Related]
6. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
8. Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.
Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG
JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL
Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824
[TBL] [Abstract][Full Text] [Related]
11. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
12. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
[TBL] [Abstract][Full Text] [Related]
13. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
Azribi F; Abdou E; Dawoud E; Ashour M; Kamal A; Al Sayed M; Burney I
BMC Cancer; 2021 Dec; 21(1):1350. PubMed ID: 34930165
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
[TBL] [Abstract][Full Text] [Related]
16. Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.
Valarmathi MT; Sawhney M; Deo SSV; Shukla NK; Das SN
Hum Mutat; 2004 Feb; 23(2):205. PubMed ID: 14722926
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 germline mutations in Chinese Hakka breast cancer patients.
Zhang Y; Wu H; Gan C; Rao H; Wang Q; Guo X
BMC Med Genomics; 2024 Jan; 17(1):3. PubMed ID: 38167124
[TBL] [Abstract][Full Text] [Related]
18. Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank.
Abul-Husn NS; Soper ER; Odgis JA; Cullina S; Bobo D; Moscati A; Rodriguez JE; ; ; Loos RJF; Cho JH; Belbin GM; Suckiel SA; Kenny EE
Genome Med; 2019 Dec; 12(1):2. PubMed ID: 31892343
[TBL] [Abstract][Full Text] [Related]
19. Cancer Risks Associated With
Li S; Silvestri V; Leslie G; Rebbeck TR; Neuhausen SL; Hopper JL; Nielsen HR; Lee A; Yang X; McGuffog L; Parsons MT; Andrulis IL; Arnold N; Belotti M; Borg Å; Buecher B; Buys SS; Caputo SM; Chung WK; Colas C; Colonna SV; Cook J; Daly MB; de la Hoya M; de Pauw A; Delhomelle H; Eason J; Engel C; Evans DG; Faust U; Fehm TN; Fostira F; Fountzilas G; Frone M; Garcia-Barberan V; Garre P; Gauthier-Villars M; Gehrig A; Glendon G; Goldgar DE; Golmard L; Greene MH; Hahnen E; Hamann U; Hanson H; Hassan T; Hentschel J; Horvath J; Izatt L; Janavicius R; Jiao Y; John EM; Karlan BY; Kim SW; Konstantopoulou I; Kwong A; Laugé A; Lee JW; Lesueur F; Mebirouk N; Meindl A; Mouret-Fourme E; Musgrave H; Ngeow Yuen Yie J; Niederacher D; Park SK; Pedersen IS; Ramser J; Ramus SJ; Rantala J; Rashid MU; Reichl F; Ritter J; Rump A; Santamariña M; Saule C; Schmidt G; Schmutzler RK; Senter L; Shariff S; Singer CF; Southey MC; Stoppa-Lyonnet D; Sutter C; Tan Y; Teo SH; Terry MB; Thomassen M; Tischkowitz M; Toland AE; Torres D; Vega A; Wagner SA; Wang-Gohrke S; Wappenschmidt B; Weber BHF; Yannoukakos D; Spurdle AB; Easton DF; Chenevix-Trench G; Ottini L; Antoniou AC
J Clin Oncol; 2022 May; 40(14):1529-1541. PubMed ID: 35077220
[TBL] [Abstract][Full Text] [Related]
20. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
